目的 研究胺碘呋酮合并丹參酮ⅡA磺酸鈉注射液用于急性心肌梗死后惡性心律失常的臨床療效及安全性。方法 篩選急性心肌梗死導致惡性心律失常的患者160例，隨機分為治療組（80例）和對照組（80例），對照組患者給予生理鹽水稀釋4 mg/kg的胺碘呋酮20 mL，iv后維持（1.25±0.25）mg/min，若癥狀緩解則酌情減少劑量；注射后若病情控制不佳，則可每隔20 min再追加（2±0.5）mg/kg的靜脈負荷量1～2次。治療組患者在對照組基礎上加用丹參酮ⅡA磺酸鈉注射液，使用前使用5%葡萄糖注射液375 mL溶解，靜脈注射，100～200 mg/次，2次/日，10～15 d為一療程，根據病情連續(xù)使用2～3個療程，治療結束后，分析兩組治療效果及不良反應。結果 治療組有效總有效率為92.5%，對照組為76.25%，兩組相比差異有統(tǒng)計學意義（P＜0.05），兩組治療后左心室射血分數和左心室短軸縮短率指標與治療前相比差異有統(tǒng)計學意義（P＜0.05）。結論 胺碘呋酮聯(lián)合丹參酮ⅡA磺酸鈉注射液是一種治療急性心肌梗死后誘發(fā)惡性心律失常較為有前景的聯(lián)合用藥。

Objective To evaluate the clinical efficiency and security of amiodaron combined with Sulfotanshinone Sodium Injection (SSI) in the treatment of malignant arrhythmia caused by acute myocardial infarction (AMI). Methods The patients (160 cases) diagnosed as AMI were randomly divided into treatment (80 cases) and control (80 cases) groups. The patients in the control group were iv administered with 20 mL amiodaron (4 mg/kg, diluted with physiological saline), then maintained the dose of (1.25 ± 0.25) mg/min. If the disease was controlled, the dosage could be reduced; if not, the dosage was increased to (2 ± 0.5) mg/kg every 20 min, once or twice. The patients in the treatment group were iv administered with SSI dissolved in 375 mL of 5% glucose, with the dose of 100—200 mg, twice daily, for 10—15 d as one course. Two groups were treated for 2—3 courses according to the disease symtom. After the treatment, the therapeutic effects and adverse reactions were observed. Results The efficiency of the patients in the treatment and control groups was 92.5% and 76.25% with the significant difference (P < 0.05). The indexes of LVEF and FS were significant difference before and after the treatments (P < 0.05). Conclusion Amiodaron combined with SSI is a relatively promising medicine for the treatment of malignant arrhythmia after AMI.